Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | STX-241 |
Synonyms | |
Therapy Description |
STX-241 is a reversible EGFR inhibitor with activity against EGFR mutations, including EGFR L858R and EGFR C797S, which potentially decreases tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): B168). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
STX-241 | STX 241|STX241 | EGFR Inhibitor 4th gen 16 | STX-241 is a reversible EGFR inhibitor with activity against EGFR mutations, including EGFR L858R and EGFR C797S, which potentially decreases tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): B168). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06567015 | Phase Ib/II | STX-241 | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs (STX-241 FIH) | Recruiting | USA | NLD | FRA | ESP | DEU | 2 |